Clinical Study
Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Table 1
Patients' Baseline Characteristics (
).
| Sex (Male/Female) | 10/5 | Age at diagnosis | 32.1 (19–52) | median (range) (years) | Age at start of the therapy | 37.2 (20–64) | median (range) (years) | Disease duration | 5.7 (0.1–21) | median (range) (years) | Extent of disease | | L1 (%) | 3 (20.0%) | L2 (%) | 7 (46.7%) | L3 (%) | 5 (33.3%) | Perianal disease (%) | 6 (40.0%) | Previous surgical resection (%) | 3 (20.0%) | Concomitant medication | | Predonisolone | 5 | 5-Aminosalicylates | 12 | Immunosuppresants (AZA) | 4 | GMA | 5 | Enteral nutrition | 4 | Anti-TNFa | 0 |
|
|
AZA: azathioprine; GMA: granulocyte and monocyte adsorptive apheresis; L1: Ileum; L2: Colon; L3: Ileocolon.
aPrevious use of infliximab or biologic.
|